Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
World J Biol Psychiatry ; 14(7): 490-9, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22424243

RESUMO

OBJECTIVES: The glutamatergic hypothesis of schizophrenia proposes alterations of excitatory amino acid transporters (solute carrier family, SLCs) expression and cerebellar dysfunctions. The influence of the neuregulin-1 (NRG1) risk genotype or effects of antipsychotics on expression of EAATs are unknown. METHODS: We compared post-mortem samples from the cerebellar hemispheres and vermis of 10 schizophrenia patients with nine normal subjects by investigating gene expression of SLC1A3, SLC1A1 and SLC1A6 by in-situ hybridization. We further assessed the allelic composition regarding the polymorphism rs35753505 (SNP8NRG221533) near the NRG1 gene. To control for effects due to antipsychotic treatment, we chronically treated rats with the antipsychotics haloperidol or clozapine and assessed gene expression of SLCs. RESULTS: Schizophrenia patients showed increased expression of SLC1A3 in the molecular layer of the vermis. Individuals carrying at least one C allele of rs35753505 (SNP8NRG221533) showed decreased expression of SLC1A6 in the molecular layer of both hemispheres, compared to individuals homozygous for the T allele. The animal model revealed suppression of SLC1A6 by clozapine. CONCLUSIONS: Increased SLC1A3 expression indicates facilitated transport and may result in reduced glutamate neurotransmission. Decreased SLC1A6 expression in NRG1 risk variant may be an adaptive effect to restore glutamate signalling, but treatment effects cannot be excluded.


Assuntos
Cerebelo/metabolismo , Transportador 1 de Aminoácido Excitatório/genética , Transportador 3 de Aminoácido Excitatório/genética , Transportador 4 de Aminoácido Excitatório/genética , Regulação da Expressão Gênica/genética , Esquizofrenia/metabolismo , Idoso , Alelos , Animais , Antipsicóticos/administração & dosagem , Antipsicóticos/uso terapêutico , Cerebelo/efeitos dos fármacos , Cerebelo/patologia , Clozapina/uso terapêutico , Modelos Animais de Doenças , Transportador 1 de Aminoácido Excitatório/biossíntese , Transportador 3 de Aminoácido Excitatório/biossíntese , Transportador 4 de Aminoácido Excitatório/biossíntese , Feminino , Haloperidol/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Neuregulina-1/genética , Polimorfismo de Nucleotídeo Único/efeitos dos fármacos , Polimorfismo de Nucleotídeo Único/genética , Ratos , Ratos Sprague-Dawley , Fatores de Risco , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética
2.
Neurosci Lett ; 474(1): 42-5, 2010 Apr 19.
Artigo em Inglês | MEDLINE | ID: mdl-20211693

RESUMO

EAAT4-eGFP BAC reporter transgenic adult mice were used to detect EAAT4 gene expression in individual cells of cerebral cortex, and eGFP fluorescence was measured to compare EAAT4 promoter activity in different cells. Most eGFP+ cells were neurons; only rare GFAP+ profiles were eGFP+. About 10% of NeuN+ cells was eGFP+, and the percentage of NeuN/eGFP co-localization varied from 2 to 20% of NeuN+ cells throughout cortical layers: layers I and II-III showed the highest values of co-localization, layer IV the lowest. The intensity of eGFP fluorescence did not exhibit laminar variations. Finally, we observed that EAAT4 promoter activity in cortical neurons was 10% of that measured in cerebellar Purkinje cells, i.e., the cells displaying the highest intensity in the CNS. These results extend our knowledge on EAAT4 expression in the cerebral cortex of adult mice, and suggest that the role of EAAT4 in cortical glutamatergic transmission may be more important than previously thought.


Assuntos
Astrócitos/metabolismo , Transportador 4 de Aminoácido Excitatório/biossíntese , Neurônios/metabolismo , Córtex Somatossensorial/metabolismo , Animais , Transportador 4 de Aminoácido Excitatório/genética , Genes Reporter , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Camundongos , Camundongos Transgênicos , Regiões Promotoras Genéticas , Células de Purkinje/metabolismo
3.
Eur J Neurosci ; 26(3): 649-56, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17686042

RESUMO

The cerebellum has been shown to be vulnerable to global ischemic damage in tightly controlled zones of Purkinje cells (PCs) that lack aldolase C, an enzyme critical for glycolysis. Here, we investigated whether aldolase C-negative PCs were more likely to die after cerebral trauma in vivo, and whether this death was mediated by excitotoxic [alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-mediated] means in vitro. Mice were subjected to controlled cortical impact, or remained uninjured, and were killed at 6 h, 24 h or 7 days after injury. Cerebellar sections (both ipsilateral and contralateral to the site of cerebral injury) were stained against aldolase C and calbindin (a marker of PCs). The number of viable, calbindin-positive PCs decreased significantly at 24 h and 7 days after injury, and the percentage of surviving, aldolase C-positive PCs significantly increased at those time-points. In addition, we subjected murine cerebellar cultures to AMPA (30 microm, 20 min), which killed a significant number of PCs at 24 h post-treatment. A similar number of PCs was lost after transfection with aldolase C siRNA, and this effect was exacerbated in transfected cultures treated with AMPA. The results from the present study indicate that aldolase C provides marked neuroprotection to PCs after trauma and excitotoxicity.


Assuntos
Lesões Encefálicas/enzimologia , Citoproteção/fisiologia , Resistência a Medicamentos/fisiologia , Frutose-Bifosfato Aldolase/metabolismo , Degeneração Neural/enzimologia , Células de Purkinje/metabolismo , Animais , Biomarcadores/metabolismo , Calbindinas , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/fisiologia , Células Cultivadas , Citoproteção/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/fisiologia , Resistência a Medicamentos/efeitos dos fármacos , Sinergismo Farmacológico , Transportador 4 de Aminoácido Excitatório/biossíntese , Frutose-Bifosfato Aldolase/genética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neurotoxinas/toxicidade , Células de Purkinje/efeitos dos fármacos , Células de Purkinje/enzimologia , RNA Interferente Pequeno/toxicidade , Proteína G de Ligação ao Cálcio S100/biossíntese , Ácido alfa-Amino-3-hidroxi-5-metil-4-isoxazol Propiônico/toxicidade
4.
Neuroscience ; 137(3): 843-51, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16297566

RESUMO

Abnormalities of the glutamatergic system in schizophrenia have been identified in numerous studies, but little is known about the role of glutamate transporters and their messenger RNA (mRNA) expression. In addition, the abundances of the two major isoforms of human excitatory amino acid transporter 2 (EAAT2) or its rat ortholog, glutamate transporter 1, have never been compared in a quantitative manner. Using quantitative reverse transcription-polymerase chain reaction, we established that the expression of the EAAT1, EAAT2a, EAAT2b, and EAAT3 transcripts was not different in the dorsolateral prefrontal and primary visual cortices of persons with schizophrenia relative to matched controls. EAAT2a expression was about 25-fold and 10-fold higher than EAAT2b in human and rat brain, respectively. The data provided no evidence of an effect of antipsychotic medications on the mRNA expression of the glutamate transporters. However, because most of the schizophrenic subjects in the cohort had been treated with antipsychotics for many years, it is still possible that changes in transporter expression were masked by medication effects.


Assuntos
Sistema X-AG de Transporte de Aminoácidos/biossíntese , Córtex Pré-Frontal/metabolismo , RNA Mensageiro/biossíntese , Esquizofrenia/metabolismo , Córtex Visual/metabolismo , Actinas/biossíntese , Animais , Antipsicóticos/farmacologia , Transportador 1 de Aminoácido Excitatório/biossíntese , Transportador 1 de Aminoácido Excitatório/genética , Transportador 4 de Aminoácido Excitatório/biossíntese , Transportador 4 de Aminoácido Excitatório/genética , Transportador 5 de Aminoácido Excitatório/biossíntese , Transportador 5 de Aminoácido Excitatório/genética , Haloperidol/farmacologia , Humanos , Células Fotorreceptoras , Córtex Pré-Frontal/efeitos dos fármacos , RNA Mensageiro/análise , RNA Mensageiro/isolamento & purificação , Ratos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Córtex Visual/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...